LKFT Lakefront Biotherapeutics NV
Stock · Amsterdam · Belgium · Healthcare · BE0003818359
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Lakefront Biotherapeutics NV, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
29.62 EUR
-1.92%
52-week range
22.32 – 30.72
Dividend yield—
Market cap2.0B
NowoTrade score
60 Grade A
Price history
Daily prices in EUR.
Updated 06 Nov 2026 17:04. Information, not advice.
Results
Next results
11 Nov 2026
in 4 days · 11:00 · estimate -0.43
Last results
0.03 vs -0.43 estimated
12 Aug 2026 · Beat +107.0%
Beat the estimate
9 of 12
3 missed · 0 in line · 4 beats in a row
Average surprise
-39.3%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 11 Nov 2026 11:00 | -0.43 | — | — | Upcoming |
| 12 Aug 2026 07:00 | -0.43 | 0.03 | +107.0% | Beat |
| 06 May 2026 17:00 | -0.51 | 0.22 | +143.6% | Beat |
| 26 Mar 2026 16:00 | 5.54 | 11.90 | +114.6% | Beat |
| 05 Nov 2025 16:00 | -0.23 | -0.18 | +22.5% | Beat |
| 23 Jul 2025 16:00 | -0.41 | -0.93 | -129.8% | Miss |
| 23 Apr 2025 16:00 | -0.19 | -2.35 | -1,107.5% | Miss |
| 12 Feb 2025 17:00 | -1.29 | 0.29 | +122.3% | Beat |
| 30 Oct 2024 16:00 | -0.20 | -0.74 | -275.4% | Miss |
| 01 Aug 2024 16:00 | -0.21 | 0.07 | +133.0% | Beat |
| 21 Feb 2024 19:00 | -3.72 | 2.39 | +164.3% | Beat |
| 02 Nov 2023 16:00 | -1.56 | 0.39 | +125.1% | Beat |
| 03 Aug 2023 16:00 | -0.90 | 0.08 | +108.9% | Beat |
| 22 Feb 2023 19:00 | -0.60 | -3.16 | -426.7% | Miss |
| 03 Nov 2022 16:00 | -0.80 | -0.54 | +32.5% | Beat |
| 04 Aug 2022 16:00 | -0.44 | -0.29 | +34.5% | Beat |
| 23 Feb 2022 19:00 | -0.79 | 0.57 | +172.3% | Beat |
| 04 Nov 2021 17:00 | -1.12 | -0.98 | +12.6% | Beat |
| 05 Aug 2021 16:00 | -0.50 | -0.99 | -98.0% | Miss |
| 06 May 2021 11:00 | -0.84 | -0.23 | +73.1% | Beat |
| 18 Feb 2021 16:00 | -1.20 | -0.84 | +30.2% | Beat |
| 05 Nov 2020 16:00 | -0.21 | -1.45 | -596.0% | Miss |
| 06 Aug 2020 16:00 | -0.33 | -1.75 | -438.5% | Miss |
| 08 May 2020 05:00 | -0.44 | -0.78 | -77.3% | Miss |
| 20 Feb 2020 16:00 | -0.16 | -1.39 | -787.3% | Miss |
| 24 Oct 2019 16:00 | 3.88 | 8.13 | +109.4% | Beat |
| 25 Jul 2019 16:00 | -1.15 | -0.87 | +24.7% | Beat |
| 25 Apr 2019 16:00 | -0.95 | -0.89 | +6.3% | Beat |
| 21 Feb 2019 16:00 | 0.50 | 0.27 | -45.6% | Miss |
| 24 Oct 2018 16:00 | -0.80 | 0.28 | +134.9% | Beat |
| 03 Aug 2018 04:00 | -0.58 | -0.42 | +27.9% | Beat |
| 25 Apr 2018 16:00 | -0.96 | -0.73 | +23.6% | Beat |
| 22 Feb 2018 17:00 | -0.26 | -0.59 | -124.3% | Miss |
| 26 Oct 2017 16:00 | -0.22 | -0.72 | -225.8% | Miss |
| 28 Jul 2017 06:00 | -0.55 | -0.74 | -34.3% | Miss |
| 27 Apr 2017 16:00 | -0.58 | -0.29 | +50.0% | Beat |
| 23 Feb 2017 17:00 | 0.47 | 0.97 | +107.3% | Beat |
| 27 Oct 2016 16:00 | -0.72 | -0.52 | +28.2% | Beat |
| 29 Jul 2016 19:00 | -0.13 | -0.10 | +23.7% | Beat |
| 28 Apr 2016 16:00 | 0.10 | 0.79 | +659.6% | Beat |
| 03 Mar 2016 16:00 | -0.85 | -1.54 | -82.0% | Miss |
| 12 Nov 2015 16:00 | -0.71 | -0.72 | -1.7% | Miss |
Annual results · EUR
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 1.1B | +303.5% | 320.9M | 28.9% | 4.87 | +334.8% | -271.3M |
| 2024 | 275.6M | +15.0% | 74.1M | 26.9% | 1.12 | -65.1% | -402.1M |
| 2023 | 239.7M | -0.6% | 211.7M | 88.3% | 3.21 | +196.7% | -425.2M |
| 2022 | 241.2M | — | -218M | -90.4% | -3.32 | — | -537.5M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 09 Feb 2024 | 36.05 | 36.95 | 35.86 | 36.81 | +2.88% | 85,409 | |
| 08 Feb 2024 | 35.75 | 36.12 | 35.56 | 35.78 | -0.11% | 35,108 | |
| 07 Feb 2024 | 36.00 | 36.27 | 35.57 | 35.82 | -0.47% | 57,855 | |
| 06 Feb 2024 | 35.32 | 35.99 | 35.32 | 35.99 | +2.59% | 64,365 | |
| 05 Feb 2024 | 34.54 | 35.08 | 34.45 | 35.08 | +1.56% | 56,775 | |
| 02 Feb 2024 | 34.82 | 35.15 | 34.54 | 34.54 | +0.12% | 30,021 | |
| 01 Feb 2024 | 35.00 | 35.00 | 34.43 | 34.50 | -1.06% | 53,672 | |
| 31 Jan 2024 | 34.81 | 34.97 | 34.54 | 34.87 | -0.40% | 50,363 | |
| 30 Jan 2024 | 35.22 | 35.54 | 34.83 | 35.01 | -0.57% | 41,594 | |
| 29 Jan 2024 | 35.00 | 35.22 | 34.67 | 35.21 | +0.40% | 67,295 | |
| 26 Jan 2024 | 34.49 | 35.07 | 34.42 | 35.07 | +1.12% | 51,442 | |
| 25 Jan 2024 | 35.20 | 35.30 | 34.61 | 34.68 | -1.81% | 56,597 | |
| 24 Jan 2024 | 35.20 | 35.53 | 35.08 | 35.32 | +0.54% | 49,829 | |
| 23 Jan 2024 | 34.90 | 35.26 | 34.90 | 35.13 | +0.95% | 51,201 | |
| 22 Jan 2024 | 34.34 | 34.85 | 34.34 | 34.80 | +0.69% | 64,161 | |
| 19 Jan 2024 | 34.70 | 34.75 | 34.03 | 34.56 | -0.40% | 120,563 | |
| 18 Jan 2024 | 35.27 | 35.34 | 34.59 | 34.70 | -2.42% | 97,358 | |
| 17 Jan 2024 | 35.50 | 35.56 | 34.94 | 35.56 | -0.22% | 79,788 | |
| 16 Jan 2024 | 35.17 | 35.84 | 34.92 | 35.64 | +0.79% | 82,805 | |
| 15 Jan 2024 | 35.56 | 35.59 | 35.34 | 35.36 | -2.00% | 75,722 | |
| 12 Jan 2024 | 36.30 | 36.68 | 35.98 | 36.08 | -0.17% | 114,552 | |
| 11 Jan 2024 | 37.00 | 37.00 | 36.14 | 36.14 | -1.95% | 128,739 | |
| 10 Jan 2024 | 38.37 | 38.37 | 36.86 | 36.86 | -4.31% | 116,548 | |
| 09 Jan 2024 | 38.71 | 38.90 | 38.07 | 38.52 | +1.53% | 84,229 | |
| 08 Jan 2024 | 37.80 | 38.03 | 37.35 | 37.94 | +0.50% | 55,984 |
Page 29 of 52
Prices in EUR, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Should You Buy Lakefront Biotherapeutics - Sponsored ADR (LKFT) After Golden Cross? (opens in a new tab) Zacks · 06 Nov 2026 13:55
- Lakefront Biotherapeutics - Sponsored ADR (LKFT) Upgraded to Buy: What Does It Mean for the Stock? (opens in a new tab) Zacks · 21 Oct 2026 16:00
- Lakefront Biotherapeutics (ENXTAM:LKFT) Stock Looks Undervalued Despite A 40% Five Year Fall (opens in a new tab) Simply Wall St. · 21 Oct 2026 06:16
- Belgian startup revives Galapagos CAR-T research (opens in a new tab) BioPharma Dive · 15 Oct 2026 16:55
- Lakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC Says (opens in a new tab) MT Newswires · 23 Sep 2026 16:00
- Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig (opens in a new tab) MarketBeat · 21 Sep 2026 10:02
- ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board (opens in a new tab) Simply Wall St. · 04 Sep 2026 23:14
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 30.20 EUR
- Market cap
- 2.0B
- Exchange
- Amsterdam
- Country
- Belgium
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- EUR
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 16.7 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 20.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 15.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 5.4 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 3.28× | Good | 31.09× |
| P/E (forward) | -5.98× | Weak | 14.98× |
| Price / book | 0.6× | Good | 3.94× |
| Price / sales | 1.97× | Good | 3.37× |
| EV / EBITDA | -0.51× | Weak | 12.96× |
| Free cash flow yield | 7.1% | Good | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 67.6% | Good | 59.2% |
| Operating margin | -359.3% | Weak | 7.4% |
| Net margin | 60.2% | Good | 3.4% |
| Return on equity | 20.1% | Good | 5.7% |
| Return on assets | 9.9% | Good | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 66.4% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0× | Good | 0.46× |
| Net debt / EBITDA | -3.93× | Good | 1.5× |
| Interest cover | 226.16× | Good | 3.26× |
| Current ratio | 32.84× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow LKFT and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.